Xtl Biopharmaceuticals (XTLB) Other Non-Current Assets (2009 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Other Non-Current Assets of $14000.0 for Q4 2025, down 92.51% year-on-year from $187000.0 in Q4 2024, and down 91.62% on a QoQ basis from $167000.0 in Q2 2025.
Xtl Biopharmaceuticals (XTLB) Other Non-Current Assets (2009 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Other Non-Current Assets for 9 consecutive years, with $14000.0 the latest figure, recorded in Q4 2025.
- Quarterly Other Non-Current Assets fell 92.51% year-over-year to $14000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14000.0 (down 92.51% YoY) and the FY2025 annual result came in at $14000.0, down 92.51% from the prior year.
- Other Non-Current Assets retreated to $14000.0 in Q4 2025 per XTLB's latest filing, from $167000.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for XTLB reached as high as $217000.0 in Q3 2024 and fell as low as $1000.0 in Q4 2021.
- A 4-year average of $84142.9 and a median of $14000.0 in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets plunged 50.0% — and 2025, when it slumped 92.51%.
- Year by year, Other Non-Current Assets stood at $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022, then jumped by 18600.0% to $187000.0 in 2024, then sank by 92.51% to $14000.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $14000.0, $167000.0, and $187000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | 14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14,000.00 |
| Jun 30, 2025 | 167,000.00 |
| Dec 31, 2024 | 187,000.00 |
| Sep 30, 2024 | 217,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Dec 31, 2019 | 2,000.00 |
| Jun 30, 2012 | 13,000.00 |
| Sep 30, 2010 | 15,000.00 |
| Jun 30, 2010 | 17,000.00 |
| Mar 31, 2010 | 20,000.00 |
| Dec 31, 2009 | 23,000.00 |
| Sep 30, 2009 | 29,000.00 |
| Jun 30, 2009 | 32,000.00 |
| Mar 31, 2009 | 36,000.00 |